In Brief: Biocontrol Technology
This article was originally published in The Gray Sheet
Biocontrol Technology: Pittsburgh, Pennsylvania-based firm announces Oct. 26 that its Diasense subsidiary has entered an agreement with Imaco Gesellschaft fur Non Invasive Systeme, GmbH for the German distribution of the Diasensor 1000 non-invasive glucose sensor. Imaco will pay $32.5 mil. for exclusive distribution rights to the product and will be required to purchase "a total of 5100 machines in 1996 at a rate of 100 for the first month and 500 a month for the next 10 months," Biocontrol says...
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.